May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Secretory leukocyte proteinase inhibitor (SLPI) expression on lacrimal and salivary glands of patients with Sjogren's syndrome after pilocarpine hydrochloride tablets treatment.
Author Affiliations & Notes
  • V.E. Reviglio
    Ophthalmology Cornea & External Diseases of the Eye,
    Fundacion VER Centro de Ojos Romagosa, Cordoba, Argentina
  • M. Foucade
    Hosp. Rivadavia, Servicio de Reumatología, Buenos aires, Argentina
  • L. Fonseca
    Hosp. Rivadavia, Servicio de Reumatología, Buenos aires, Argentina
  • A. Catalan Pellet
    Hosp. Rivadavia, Servicio de Reumatología, Buenos aires, Argentina
  • J.D. Luna
    Ophthalmology,
    Fundacion VER Centro de Ojos Romagosa, Cordoba, Argentina
  • C.P. Juarez
    Ophthalmology,
    Fundacion VER Centro de Ojos Romagosa, Cordoba, Argentina
  • A. Berra
    Depto de Patología, UBA, Laboratorio de Inmunología, Buenos aires, Argentina
  • Footnotes
    Commercial Relationships  V.E. Reviglio, None; M. Foucade, None; L. Fonseca, None; A. Catalan Pellet, None; J.D. Luna, None; C.P. Juarez, None; A. Berra, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3886. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V.E. Reviglio, M. Foucade, L. Fonseca, A. Catalan Pellet, J.D. Luna, C.P. Juarez, A. Berra; Secretory leukocyte proteinase inhibitor (SLPI) expression on lacrimal and salivary glands of patients with Sjogren's syndrome after pilocarpine hydrochloride tablets treatment. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3886.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the expression of SLPI in lacrimal and salivary glands from patients with primary Sjogren's syndrome before and after oral pilocarpine treatment. Methods: Ten patients with Sjogren's syndrome and 10 healthy controls were used. After providing written informed consent, the patients with primary SS and clinically significant dry mouth and dry eyes were randomized to receive 5–mg pilocarpine, or placebo tablets 4 times daily for 20 weeks. All individuals underwent a systemic and ophthalmological evaluation, lacrimal and salivary glands biopsies were performed before and after pilocarpine treatment. Sections from the gland biopsies were stained with hematoxylin and eosin. Immunohistochemical (SLPI) and apoptosis staining was performed. Sialometry pre and post treatment were made. Results: The light microscopic examination revealed the presence of a mononuclear infiltration in the salivary and lacrimal glands of patients with Sjogren's syndrome before pilocarpine treatment, with intense SLPI and apoptosis staining results. Acinar expression was variable and weaker than that seen in ducts. In contrast, sections of healthy individuals and from patients with oral pilocarpine treatment revealed a weak immuno–staining and decreased lymphocyte infiltration. Conclusion: These results demonstrate complex and variable changes in ductal expression of SLPI in primary SS, which may be important in the control of lymphoid infiltration and help to attenuate potential inflammation during clearance of apoptotic cells and tissue remodelling.

Keywords: cornea: tears/tear film/dry eye • autoimmune disease • lacrimal gland 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×